Compare ICHR & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICHR | IVA |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | France |
| Employees | N/A | 84 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2016 | N/A |
| Metric | ICHR | IVA |
|---|---|---|
| Price | $48.43 | $6.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $40.67 | $16.20 |
| AVG Volume (30 Days) | ★ 1.2M | 397.8K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $947,652,000.00 | N/A |
| Revenue This Year | $16.08 | N/A |
| Revenue Next Year | $11.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.61 | N/A |
| 52 Week Low | $13.15 | $2.70 |
| 52 Week High | $55.00 | $7.98 |
| Indicator | ICHR | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 50.40 |
| Support Level | $15.70 | $5.71 |
| Resistance Level | N/A | $6.48 |
| Average True Range (ATR) | 4.08 | 0.29 |
| MACD | -0.32 | -0.03 |
| Stochastic Oscillator | 55.63 | 29.86 |
Ichor Holdings Ltd designs, engineers, and manufactures critical fluid delivery subsystems and components mainly for semiconductor capital equipment, along with solutions for defense/aerospace and medical industries. Its product portfolio includes gas and chemical delivery subsystems that enable precise delivery, monitoring, and control of specialized gases and reactive liquid chemistries used in semiconductor manufacturing processes such as etch, electroplating, and cleaning. The company also provides precision-machined components, weldments, e-beam and laser-welded components, as well as precision vacuum and hydrogen brazing. Geographically, the company operates across the United States, Singapore, Europe, and other regions, with Singapore contributing the majority of revenue.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.